本报讯 （记者梁傲男）12月13日，由中国抗癌协会与京东健康共同发起的肿瘤整合防治工程正式启 动，同期，2025肿瘤防治新进展大会在京举行。 大会汇聚由中国工程院院士、中国抗癌协会理事长樊代明领衔的顶尖专家阵容，聚焦肿瘤领域学术新进 展、医工交叉新技术、专病大模型及科研成果转化等前沿和热点议题，打造了一场肿瘤防治的学术盛 宴。 京 东供图 在肿瘤专科建设及专病防治方面，依然存在医疗资源分布不均、临床决策复杂、科研转化滞后、患者管 理低效等系统性挑战。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面加速"医检诊药"闭环， 打造AI京医专业服务智能体、专家医生智能体、RWD科研平台，以医疗级AI为目标，形成资源可及、 决策可依、科研可转化、患者可管理的智能肿瘤防治体系，为医生赋能、为患者服务、为行业提效。 京东集团SEC委员、京东健康CEO曹冬表示，作为中国肿瘤防治事业的参与者和推动者，京东健康始终 坚持"以专业守护生命"的理念，携手中国抗癌协会等权威机构，系统推进从科普教育、早筛早诊到规范 诊疗、康复管理的全程服务，切实守护大众健康。未来，京东健康将持续与各方合作伙伴并肩，深化人 工智 ...

目前，京东互联网医院肿瘤专科已全面升级，通过权威三甲医院专家团队与AI智能技术结合，构建"筛 查、诊断、治疗、随访"一体化服务体系。据悉，该肿瘤专科已有3万余名三甲医院权威专家。 会上，京东健康分别与广州医科大学附属第一医院、中山大学孙逸仙纪念医院、北京大学肿瘤医院进行 AI专病课题合作签约。聚焦消化道肿瘤、前列腺癌及呼吸系统等方向，京东健康将基于京医千询大模 型技术能力，携手三大医疗机构围绕AI在影像识别、病情动态监测与辅助诊疗等方面的创新应用与前 沿进展进行深度合作。 新浪科技讯 12月14日上午消息，昨日，在2025肿瘤防治新进展大会上，京东健康与中国抗癌协会共同 发起"肿瘤整合防治工程（2025-2030）"，构建"防-筛-诊-治-康"全流程体系，将AI等前沿技术深度融合 于临床实践，探索肿瘤防治的中国路径。 针对肿瘤科普内容真伪难辨、大众对肿瘤早筛重视不足等痛点，京东健康与中国抗癌协会将推出肿瘤防 治科普行动；围绕医疗资源均衡可及、基层医院专科建设等需求，双方将推出肿瘤医生赋能计划；此 外，双方还将开展肿瘤康复技术产学研合作。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面 ...

研究员：洪依真/林起贤/刘洋/张静含/周文远/任梦妮/陈晴华/黄俊儒 机构：申万宏源研究 风险提示：互联网医疗政策环境变化、线上渗透率不及预期、行业竞争加剧。 自营医药为核心，拓展至综合医疗健康服务。京东健康为京东集团在医疗健康领域的核心子公司，14 年2 月至今已从医药电商拓展为涵盖健康商品销售和营销、医疗健康服务、企业健康解决方案、智慧医 疗解决方案等的综合服务商。 竞争趋缓，供应链+服务+AI 协同破局。2021 年起互联网医疗的竞争激烈，以美团买药为代表的O2O、 以抖音快手平台为代表的短视频直播电商带来了大健康领域竞争格局的较大变化，至2025 年互联网医 疗电商的竞争或陆续趋于平缓。公司除供应链优势外，服务生态上已形成医检诊药闭环，AI 技术端发 布京医千询大模型并开源，构建用户、医生、医院端产品矩阵，多方协同下有望打开未来增长空间。 首次覆盖，给予买入评级。考虑到公司供应链优势、自营品牌优势、持续引入第三方商家和拓展O2O 下能推动业绩稳健增长， 我们预测2025-2027 年收入预计为636.5/696.5/765.5 亿，归母净利润分别为 45.2/50.4/57.9 亿。考虑到公司在供应链 ...

Core Insights - JD Health is gaining significant attention from Liu Qiangdong and Xu Ran, especially following the recent 618 shopping festival, where it showcased its marketing strategies prominently [1][5] - The company reported a total revenue of 58.16 billion in 2024, with a profit of 4.157 billion, marking a 94% increase compared to 2023 [1][5] - JD Health is positioned as the leader in the B2C pharmaceutical market, outperforming Alibaba Health, which is projected to generate 30.598 billion in revenue for the 2025 fiscal year [5][8] Group 1: Market Position and Growth - JD Health's market capitalization is over 100 billion HKD, approximately one-third of JD Group's total market value [5] - The company achieved a growth rate of 25.5% in the first quarter of 2023, driven by the online medical insurance payment initiative [8] - The B2C pharmaceutical e-commerce market reached sales of 66.3 billion in 2023, with a growth rate of 15.3% [12] Group 2: Competitive Landscape - The online pharmaceutical market is highly competitive, with JD Health, Meituan, and Ele.me vying for market share [11][12] - Meituan currently holds a 70% market share in the national O2O pharmaceutical sector, posing a challenge for JD Health [17] - JD Health's "Buy Medicine Fast" initiative aims to capture the online medical insurance market, with a focus on rapid delivery and quality service [15][11] Group 3: Future Opportunities - The integration of AI and health consumption trends presents new opportunities for JD Health, particularly in personalized health products and services [4][18] - The company is exploring the potential of AI models to enhance its service offerings, including AI nutritionists and medical assistants [18][20] - The demand for weight management products has surged, with JD Health reporting a threefold increase in sales for weight loss medications [26][28] Group 4: Strategic Focus - JD Health is focusing on expanding its product offerings beyond pharmaceuticals to include health and wellness products, aligning with the growing trend of preventive healthcare [23][24] - The company aims to leverage its expertise in e-commerce to support local pharmaceutical companies and enhance its market presence [26][28] - The market is optimistic about JD Health's future, with a projected price-to-earnings ratio of nearly 30 times based on its 2024 net profit [29]